Victoria Socha

DocwireNews

In patients with diabetic kidney disease (DKD), concerns regarding hyperkalemia may result in underutilization of both established and novel therapies aimed at improving kidney and/or cardiovascular outcomes. Concerns related to hyperkalemia are particularly relevant in patients with CKD who are receiving other hyperkalemia-inducing agents such as renin-angiotensin-aldosterone system (RAAS) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (nsMRA).Results of clinical trials have suggested that the risk of severe hyperkalemia is mitigated with the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Rehab B. Albakr, MD, and colleagues presented a review of recent evidence associated with the risk of hyperkalemia in patients with type 2 diabetes and chronic kidney diseas (CKD). The review focused on SGLT2 inhibitors and nsMRA.The researchers concluded that SGLT2 inhibitors can be used safely in patients with type 2 diabetes and CKD at high cardiovascular risk with no increase in the risk of hyperkalemia. When finerenone is used as a renal and cardiovascular protective agent in patients with type 2 diabetes, routine monitoring of potassium is generally required. Existing data indicate that when added to standard of care, SGLT2 inhibitors in combination with finerenone are safe and may exert additional cardiorenal benefits in patients with DKD.&ldquo;The use of potassium binders should be considered to enable optimal doses of guideline-based therapies for patients with DKD to maximize the kidney and cardiovascular benefits,&rdquo; the researchers said.Source: <a href="https://www.ajkd.org/article/S0272-6386(23)00743-6/fulltext" target="_blank" rel="noopener">American Journal of Kidney Diseases</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Evidence Review of Novel Therapies for DKD and Risk of Hyperkalemia

Hyperkalemia

The study found that SGLT2 inhibitors can be used safely in patients with type 2 diabetes and CKD at high cardiovascular risk with no increase in the risk of hyperkalemia.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe